ProCE Banner Activity

CheckMate 816: Association of Pathologic Features With Efficacy Outcomes for Neoadjuvant Nivolumab + Platinum-Doublet CT in Resectable NSCLC

Slideset Download
Conference Coverage
Results from a post hoc analysis of the CheckMate 816 study showed improved pathologic complete response and EFS with neoadjuvant nivolumab plus platinum-doublet CT in patients with resectable NSCLC regardless of lymph node involvement.

Released: September 16, 2022

Expiration: September 15, 2023

Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp